Sierra Oncology, Inc. [SRRA]

Source: 

Company Overview

We are a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer. Our main focus is the development and potential commercialization of momelotinib, an investigational agent for the treatment of myelofibrosis. In January 2022, we announced positive topline results from our global Phase 3 clinical trial for patients with myelofibrosis called MOMENTUM. Momelotinib achieved a statistically significant benefit on symptoms, anemia and splenic size. MOMENTUM data, combined with data from our earlier clinical trials, will be the basis for a New Drug Application (NDA) we plan to submit to the U.S. Food and Drug Administration (FDA) in the second quarter of 2022.